Premium
Imunohistochemical characterization and amplification of Erb‐family in preneoplasia lesions of respiratory epithelia
Author(s) -
Carvalho Lina,
Sousa Vitor,
Silva Maria
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.4.a215-b
Subject(s) - dysplasia , carcinoma in situ , pathology , polysomy , atypical adenomatous hyperplasia , immunohistochemistry , carcinoma , in situ hybridization , hyperplasia , medicine , adenocarcinoma , biology , cancer , gene expression , gene , biochemistry
Background An earlier diagnosis of preneoplastic lesions could have good impact on lung cancer prognosis. The pre‐invasive lesions according to WHO criteria are dysplasia and carcinoma in situ for squamous cell carcinoma. Basal cell hyperplasia and metaplasia are considered preneoplastic lesions. The Erb‐B family of receptors play an important role in tumor development, including bronchial preneoplasia. In invasive tumors, EGFR is expressed in 50–90%, mostly in squamous cell carcinomas, while HER2 is less frequently expressed (20–30%), mostly in adenocarcinomas. Methods 50 bronchial biopsy specimens with preneoplastic lesions were studied by immunohistochemistry using antibodies against LP34, CK7, Cromo A, p53, c‐erbB‐2 and EGFR. HER2 and EGFR gene copy numbers per cell were evaluated by fluorescent in situ hybridization. Analyses were independently evaluated by two investigators. Results Differentiation markers such as LP34, CK7 and Cromo A allowed us to accurately differentiate preneoplastic lesions of the bronchial epithelial. Expression of p53 was also found in preneoplasic lesions, especially in dysplasia and carcinoma in situ . Polysomy was found early in the hyperplasia‐metaplasia‐dysplasia sequence independently on the type of the lesion. Amplification of HER2/neu and EGFR occur more frequently in dysplasia and carcinoma in situ . Conclusion The expression of p53 occurs in all stages of preneoplasic lesions. Genetic and protein expression of EGFR and HER2/neu are detected in preneoplastic lesions with increased expression in pre‐invasive lesions like dysplasia and carcinoma in situ.